| Dr Roger Keith Ottman, MD | |
|
1512 12th Ave Rd, Nampa, ID 83686-6008 | |
| (208) 463-5100 | |
| Not Available |
| Full Name | Dr Roger Keith Ottman |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 47 Years |
| Location | 1512 12th Ave Rd, Nampa, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790705283 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | M-3812 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tucson Medical Center | Tucson, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ies Arizona Pllc | 7810382884 | 32 |
News Archive
As they pop the champagne corks to celebrate New Year's Eve, drug industry executives will likely be glad to put 2009 behind them. That's because pharmaceutical companies who make top-selling drugs for heart disease, asthma, and many other conditions had a tough year in the midst of mounting market pressures and a global recession.
EpiCept Corporation today announced that the Israeli Ministry of Health has approved the marketing application for Ceplene®, indicated for remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. Megapharm Ltd. is EpiCept's partner in Israel and upon Ministry of Health approval of labeling and other technical matters the company is expected to launch Ceplene® in the first quarter of 2011.
SIRS-Lab GmbH, a molecular diagnostics company based in Jena, Germany, and Pfizer Pharma GmbH, headquartered in Berlin, have announced a collaboration in the field of sepsis.
Researchers have developed cancer drug-packed 'grenades' armed with heat sensitive triggers, allowing for treatment to be targeted directly at tumours, according to two studies due to be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
› Verified 1 days ago
| Entity Name | Ies Arizona Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821752213 PECOS PAC ID: 7810382884 Enrollment ID: O20220310001059 |
News Archive
As they pop the champagne corks to celebrate New Year's Eve, drug industry executives will likely be glad to put 2009 behind them. That's because pharmaceutical companies who make top-selling drugs for heart disease, asthma, and many other conditions had a tough year in the midst of mounting market pressures and a global recession.
EpiCept Corporation today announced that the Israeli Ministry of Health has approved the marketing application for Ceplene®, indicated for remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. Megapharm Ltd. is EpiCept's partner in Israel and upon Ministry of Health approval of labeling and other technical matters the company is expected to launch Ceplene® in the first quarter of 2011.
SIRS-Lab GmbH, a molecular diagnostics company based in Jena, Germany, and Pfizer Pharma GmbH, headquartered in Berlin, have announced a collaboration in the field of sepsis.
Researchers have developed cancer drug-packed 'grenades' armed with heat sensitive triggers, allowing for treatment to be targeted directly at tumours, according to two studies due to be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
› Verified 1 days ago
| Entity Name | Ies Obs Arizona Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356006670 PECOS PAC ID: 7719364991 Enrollment ID: O20220509000853 |
News Archive
As they pop the champagne corks to celebrate New Year's Eve, drug industry executives will likely be glad to put 2009 behind them. That's because pharmaceutical companies who make top-selling drugs for heart disease, asthma, and many other conditions had a tough year in the midst of mounting market pressures and a global recession.
EpiCept Corporation today announced that the Israeli Ministry of Health has approved the marketing application for Ceplene®, indicated for remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. Megapharm Ltd. is EpiCept's partner in Israel and upon Ministry of Health approval of labeling and other technical matters the company is expected to launch Ceplene® in the first quarter of 2011.
SIRS-Lab GmbH, a molecular diagnostics company based in Jena, Germany, and Pfizer Pharma GmbH, headquartered in Berlin, have announced a collaboration in the field of sepsis.
Researchers have developed cancer drug-packed 'grenades' armed with heat sensitive triggers, allowing for treatment to be targeted directly at tumours, according to two studies due to be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Roger Keith Ottman, MD 1100 River Heights Dr, Meridian, ID 83642-5166 Ph: (208) 841-1814 | Dr Roger Keith Ottman, MD 1512 12th Ave Rd, Nampa, ID 83686-6008 Ph: (208) 463-5100 |
News Archive
As they pop the champagne corks to celebrate New Year's Eve, drug industry executives will likely be glad to put 2009 behind them. That's because pharmaceutical companies who make top-selling drugs for heart disease, asthma, and many other conditions had a tough year in the midst of mounting market pressures and a global recession.
EpiCept Corporation today announced that the Israeli Ministry of Health has approved the marketing application for Ceplene®, indicated for remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. Megapharm Ltd. is EpiCept's partner in Israel and upon Ministry of Health approval of labeling and other technical matters the company is expected to launch Ceplene® in the first quarter of 2011.
SIRS-Lab GmbH, a molecular diagnostics company based in Jena, Germany, and Pfizer Pharma GmbH, headquartered in Berlin, have announced a collaboration in the field of sepsis.
Researchers have developed cancer drug-packed 'grenades' armed with heat sensitive triggers, allowing for treatment to be targeted directly at tumours, according to two studies due to be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
› Verified 1 days ago
Dr. Richard C Ballantyne, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 215 E Hawaii Ave, Nampa, ID 83686 Phone: 208-364-3000 | |
Dr. Eric Paul Kendall, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1512 12th Ave Rd, Nampa, ID 83686 Phone: 208-463-5100 | |
William R England, M.D Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 215 E Hawaii Ave, Nampa, ID 83686 Phone: 208-463-3234 Fax: 208-463-3044 | |
Thomas Ronay, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 85 S Middleton Rd, Nampa, ID 83651 Phone: 208-505-2800 | |
John Mullins, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1115 12th Ave Rd, Nampa, ID 83686 Phone: 208-498-1080 | |
Dr. Mitchell D Long, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1512 12th Ave Rd, Nampa, ID 83686 Phone: 208-463-5100 |